Schonfeld Strategic Advisors’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.26M | Sell |
77,068
-210,233
| -73% | -$11.6M | 0.03% | 553 |
|
|
2025
Q1 | $13.9M | Buy |
+287,301
| New | +$13.9M | 0.08% | 210 |
|
|
2024
Q4 | – | Sell |
-61,026
| Closed | -$2.75M | – | 2175 |
|
|
2024
Q3 | $2.75M | Buy |
61,026
+11,962
| +24% | +$538K | 0.02% | 641 |
|
|
2024
Q2 | $1.7M | Buy |
+49,064
| New | +$1.7M | 0.01% | 862 |
|
|
2024
Q1 | – | Sell |
-89,113
| Closed | -$2.04M | – | 2123 |
|
|
2023
Q4 | $2.04M | Sell |
89,113
-64,985
| -42% | -$1.49M | 0.01% | 729 |
|
|
2023
Q3 | $2.57M | Buy |
+154,098
| New | +$2.57M | 0.02% | 642 |
|
|
2023
Q2 | – | Sell |
-148,992
| Closed | -$3.43M | – | 2261 |
|
|
2023
Q1 | $3.43M | Buy |
+148,992
| New | +$3.43M | 0.03% | 541 |
|
|
2022
Q4 | – | Sell |
-31,814
| Closed | -$268K | – | 2818 |
|
|
2022
Q3 | $268K | Sell |
31,814
-16,218
| -34% | -$137K | ﹤0.01% | 2114 |
|
|
2022
Q2 | $380K | Buy |
48,032
+34,332
| +251% | +$272K | ﹤0.01% | 1452 |
|
|
2022
Q1 | $325K | Buy |
+13,700
| New | +$325K | ﹤0.01% | 1582 |
|
|
2021
Q3 | – | Sell |
-5,000
| Closed | -$224K | – | 2246 |
|
|
2021
Q2 | $224K | Buy |
+5,000
| New | +$224K | ﹤0.01% | 1569 |
|
|
2019
Q3 | – | Sell |
-101,800
| Closed | -$1.23M | – | 1179 |
|
|
2019
Q2 | $1.23M | Buy |
101,800
+77,800
| +324% | +$942K | 0.04% | 390 |
|
|
2019
Q1 | $301K | Buy |
+24,000
| New | +$301K | 0.01% | 833 |
|